{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:50:55Z","timestamp":1774461055196,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.bbr.2014.09.046","type":"journal-article","created":{"date-parts":[[2014,10,7]],"date-time":"2014-10-07T23:07:19Z","timestamp":1412723239000},"page":"186-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats"],"prefix":"10.1016","volume":"278","author":[{"given":"Kazuaki","family":"Kawaura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohnosuke","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiji","family":"Kambe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Kaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-ichi","family":"Karasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeyuki","family":"Chaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohiko","family":"Hikichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2014.09.046_bib0005","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00213-003-1709-2","article-title":"The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia","volume":"174","author":"Coyle","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2014.09.046_bib0010","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.bbr.2014.09.046_bib0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00213-003-1582-z","article-title":"NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development","volume":"169","author":"Krystal","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2014.09.046_bib0020","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0022-3956(99)00029-1","article-title":"NMDA receptor hypofunction model of schizophrenia","volume":"33","author":"Olney","year":"1999","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.bbr.2014.09.046_bib0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/hrp.7.3.125","article-title":"NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders","volume":"7","author":"Krystal","year":"1997","journal-title":"Harv Rev Psychiatry"},{"key":"10.1016\/j.bbr.2014.09.046_bib0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0893-133X(94)00131-I","article-title":"Subanesthetic doses of ketamine stimulate psychosis in schizophrenia","volume":"13","author":"Lahti","year":"1995","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2014.09.046_bib0035","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/0896-6273(92)90207-T","article-title":"Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors","volume":"8","author":"Smith","year":"1992","journal-title":"Neuron"},{"key":"10.1016\/j.bbr.2014.09.046_bib0040","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1152\/jn.1996.76.5.3415","article-title":"Glycine regulation of synaptic NMDA receptors in hippocampal neurons","volume":"76","author":"Wilcox","year":"1996","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.bbr.2014.09.046_bib0045","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1152\/jn.00680.2002","article-title":"Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo","volume":"89","author":"Chen","year":"2003","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.bbr.2014.09.046_bib0050","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0014-2999(94)90766-8","article-title":"d-Cycloserine, a partial agonist at the glycine site, enhances the excitability of dentate granule cells in vivo in rats","volume":"253","author":"Pitk\u00e4nen","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2014.09.046_bib0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pbb.2008.06.009","article-title":"Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia","volume":"91","author":"Boulay","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.bbr.2014.09.046_bib0060","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/sj.npp.1300772","article-title":"Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic","volume":"30","author":"Depoort\u00e8re","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2014.09.046_bib0065","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.phrs.2009.12.010","article-title":"Antipsychotic-like effects of the N-methyl-D-aspartate receptor modulator neboglamine: an immunohistochemical and behavioural study in the rat","volume":"61","author":"Chiusaroli","year":"2010","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bbr.2014.09.046_bib0070","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbr.2007.07.033","article-title":"D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats","volume":"186","author":"Karasawa","year":"2008","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bbr.2014.09.046_bib0075","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00213-010-1794-y","article-title":"D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats","volume":"209","author":"Shimazaki","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2014.09.046_bib0080","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00213-008-1289-2","article-title":"Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat","volume":"202","author":"Black","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2014.09.046_bib0085","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0006-3223(03)00707-8","article-title":"High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia","volume":"55","author":"Heresco-Levy","year":"2004","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bbr.2014.09.046_bib0090","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0006-3223(98)00279-0","article-title":"D-Serine added to antipsychotics for the treatment of schizophrenia","volume":"44","author":"Tsai","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bbr.2014.09.046_bib0095","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.biopsych.2003.09.012","article-title":"Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia","volume":"55","author":"Tsai","year":"2004","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bbr.2014.09.046_bib0100","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.4088\/JCP.11m07031","article-title":"A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia","volume":"73","author":"Weiser","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.bbr.2014.09.046_bib0105","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/JCP.0000000000000073","article-title":"The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial","volume":"34","author":"Schoemaker","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.bbr.2014.09.046_bib0110","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1111\/j.1476-5381.1995.tb15106.x","article-title":"Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia","volume":"116","author":"Noda","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bbr.2014.09.046_bib0115","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00213-011-2567-y","article-title":"Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test","volume":"221","author":"Langen","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2014.09.046_bib0120","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.pnpbp.2012.04.018","article-title":"Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia","volume":"38","author":"Chindo","year":"2012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.bbr.2014.09.046_bib0125","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00004714-199406000-00008","article-title":"Clozapine effects on positive and negative symptoms: a six-month trial in treatment-refractory schizophrenics","volume":"14","author":"Lindenmayer","year":"1994","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.bbr.2014.09.046_bib0130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0010-440X(94)90164-3","article-title":"Clozapine's effect on negative symptoms in treatment-refractory schizophrenics","volume":"35","author":"Miller","year":"1994","journal-title":"Compr Psychiatry"},{"key":"10.1016\/j.bbr.2014.09.046_bib0135","first-page":"379","article-title":"Positive and negative schizophrenia: More than one disease process","volume":"137","author":"Crow","year":"1986","journal-title":"Br Med J"},{"key":"10.1016\/j.bbr.2014.09.046_bib0140","series-title":"The rat brain in stereotaxic coordinates","author":"Paxinos","year":"1997"},{"key":"10.1016\/j.bbr.2014.09.046_bib0145","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ab.2012.09.035","article-title":"A surrogate analyte method to determine D-serine in mouse brain using liquid chromatography-tandem mass spectrometry","volume":"432","author":"Kinoshita","year":"2013","journal-title":"Anal Biochem"},{"key":"10.1016\/j.bbr.2014.09.046_bib0150","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbr.2009.02.007","article-title":"Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801","volume":"204","author":"Seillier","year":"2009","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bbr.2014.09.046_bib0155","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/sj.bjp.0701164","article-title":"The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats","volume":"121","author":"Okuyama","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bbr.2014.09.046_bib0160","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0024-3205(01)01262-0","article-title":"Effect of ACTH on the imipramine- and desipramine-induced decrease in duration of immobility time as measured in a rat forced swimming test","volume":"69","author":"Takamori","year":"2001","journal-title":"Life Sci"},{"key":"10.1016\/j.bbr.2014.09.046_bib0165","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3109\/10401239709147802","article-title":"The effects of clozapine on negative symptoms in patients with schizophrenia with minimal positive symptoms","volume":"9","author":"Brar","year":"1997","journal-title":"Ann Clin Psychiatry"},{"issue":"Suppl","key":"10.1016\/j.bbr.2014.09.046_bib0170","first-page":"22","article-title":"Negative symptoms in schizophrenia: assessment of the effect of risperidone","volume":"55","author":"Schooler","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.bbr.2014.09.046_bib0175","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000418016","article-title":"Treatment of positive and negative symptoms: pharmacologic approaches","volume":"24","author":"Boyer","year":"1990","journal-title":"Mod Probl Pharmacopsychiatry"},{"key":"10.1016\/j.bbr.2014.09.046_bib0180","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/266730a0","article-title":"Depression: a new animal model sensitive to antidepressant treatments","volume":"266","author":"Porsolt","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2014.09.046_bib0185","doi-asserted-by":"crossref","first-page":"e83879","DOI":"10.1371\/journal.pone.0083879","article-title":"Mice lacking NMDA receptors in parvalbumin neurons display normal depression-related behavior and response to antidepressant action of NMDAR antagonists","volume":"9","author":"Pozzi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbr.2014.09.046_bib0190","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2006.10.010","article-title":"CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia","volume":"90","author":"Bendikov","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.bbr.2014.09.046_bib0195","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.psychres.2009.11.008","article-title":"Glycine serum level in schizophrenia: relation to negative symptoms","volume":"176","author":"Hons","year":"2010","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.bbr.2014.09.046_bib0200","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bbr.2007.03.003","article-title":"Hypofunctional glutamatergic neurotransmission in the prefrontal cortex is involved in the emotional deficit induced by repeated treatment with phencyclidine in mice: implications for abnormalities of glutamate release and NMDA-CaMKII signaling","volume":"180","author":"Murai","year":"2007","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bbr.2014.09.046_bib0205","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","article-title":"Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study","volume":"71","author":"Umbricht","year":"2014","journal-title":"JAMA Psychiatry"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432814006445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432814006445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T19:21:00Z","timestamp":1565896860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432814006445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":41,"alternative-id":["S0166432814006445"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2014.09.046","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2014.09.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}